RESUMEN
Background: BCR-ABL negative myeloproliferative neoplasms [MPN] include polycythemia Vera [PV], essential thrombocythemia [ET] and primitive myelofibrosis [PMF]. the JAK2 V617F mutation has been introduced since 2008 as a major diagnostic criterion on the one hand and on the other hand, it would be linked to increased risk of thrombotic complications
Aim: This study aimed to evaluate the association of JAK2 mutation and thrombotic events in MPN
Methods:A retrospective study concerning 45 BCR-ABL negative MPN patients [mean age=53 old years, sex ratio=0.8] was conducted
Results: They were classified as PV [22 patients], ET [17 patients], PMF [3 patients] and atypical MPN [3 patients]. The JAK2 mutation was found in 64.4% of patients: 72.7% of PV patients, 47% of ET patients and 66.7% of PMF patients. Thrombotic events were recorded in 11 patients [24.4%]. Cerebral arteries and portal vein were the most frequent localizations. The JAK2 mutation was an independent risk factor of thrombotic events
Conclusion: Consequently, it seems that screening for JAK2 mutation in BCR-ABL negative MPN could play a role in identifying patients at high risk of vascular complications